PDS Biotechnology Corp quarterly report, Q1 FY2018

Filing identity and reporting period

Important: The supplied filing is Edge Therapeutics, Inc.’s Form 10-Q for the quarter ended March 31, 2018, not a PDS Biotechnology Corp. filing. The summary below describes the filing text provided.

Business context

Edge was a clinical-stage biotechnology company with no approved products or product revenue. On March 28, 2018, it reported that an interim analysis of its Phase 3 NEWTON 2 trial of EG-1962 indicated a low probability of meeting the primary endpoint. Following the independent monitoring committee’s recommendation, Edge stopped the trial, ceased EG-1962 development, and suspended research on its other candidates. The committee reported no safety concerns attributed to EG-1962.

Financial performance and position

Cash and cash equivalents were $75.0 million at March 31, 2018, down from $88.1 million at December 31, 2017. Current liabilities were $32.3 million and current assets were $75.9 million. The $20.0 million Hercules loan was reclassified as short-term debt because the lender could have acceleration rights following the trial halt; Hercules had not declared a default and said it would defer discussion until late in Q2 2018. The loan’s effective interest rate was 9.40%. No operating margin is meaningful given the absence of revenue and operating losses.

Material changes, outlook, and risks

• R&D expense rose primarily from NEWTON 2 trial costs and estimated close-down costs; the $2.7 million impairment reflected the reduced expected value of manufacturing equipment.
• Management expected R&D spending to decline as programs were wound down and stated that existing cash was expected to fund anticipated needs for at least 12 months. That estimate was subject to significant uncertainty and depended on cash management and strategic-review costs.
• In April 2018, Edge began exploring strategic alternatives, including a sale, merger, acquisition, or other transaction, with Piper Jaffray as financial adviser. No outcome or timetable was assured; management also disclosed that dissolution and liquidation could be considered if no transaction succeeded.
• A May 1, 2018 workforce-reduction announcement, subsequent to quarter-end, planned to reduce headcount from 37 to 8. The company estimated approximately $4.9 million in restructuring charges and $5.9 million in annualized savings, potentially partly offset by outsourced-service costs. A separate subsequent-event note cited a $3.724 million severance charge; the filing text does not reconcile these estimates.
• A purported securities class action filed in April 2018 alleged misleading statements related to EG-1962. The company intended to defend itself and could not estimate the outcome or potential loss. The filing also disclosed a FINRA inquiry relating to trading around the trial announcement.
• Other significant exposures include contractual wind-down and termination costs, executive severance obligations, lease payments, debt covenants and possible loan acceleration, and uncertainty over the strategic process and Nasdaq listing.

Key facts for investors to verify

• Confirm the intended issuer: the provided filing is for Edge Therapeutics, not PDS Biotechnology Corp.
• Review the full NEWTON 2 interim-analysis results when available and the status of any remaining product candidates.
• Confirm Hercules’ position on default, acceleration, repayment terms, and any consent needed for a strategic transaction.
• Reconcile the workforce-reduction charge estimates and verify actual severance costs, timing, and realized savings.
• Track the strategic alternatives process, potential liquidation, litigation, and any resulting obligations or changes to cash runway.